ArticleCanadian liver journal2025
Prevalence and severity of MASLD and fibrosis using transient elastography: A cross-sectional screening in Lower Mainland, British Columbia, Canada.
Article in Canadian liver journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of liver disease worldwide. We aimed to assess the prevalence and severity of MASLD and fibrosis among asymptomatic individuals with no known history of liver disease in British Columbia (BC), Canada. Methods: We conducted a cross-sectional, population-based screening study of 2,782 individuals in the Lower Mainland of BC. Baseline demographics were collected, and transient elastography was performed. The prevalence and severity of MASLD and liver fibrosis were calculated. Results: MASLD affected 53.1% of participants, with 34.0% having severe hepatic steatosis, 6.5% moderate hepatic steatosis, and 12.6% mild hepatic steatosis. Factors associated with a higher MASLD incidence included non-lean BMI (OR 5.50, Conclusions: There is a significant burden of liver steatosis and fibrosis in BC, Canada, which highlights the need for comprehensive MASLD screening guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.